glumetinib: Clinical Trials

10 trials of glumetinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 not yet recruiting, 3 recruiting, 1 unknown. 6 Phase 2, 5 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Not yet recruiting 3, Recruiting 2, Unknown 1
Phase 15Completed 3, Recruiting 1, Unknown 1
Phase 32Not yet recruiting 1, Recruiting 1

Follow glumetinib: new trials by email Literature Review of glumetinib trials Research Report on glumetinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Glumetinib Tablets, Docetaxel for Injection (Albumin-bound) - Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Phase 2RecruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.3502025-06-042025-09-08
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Glumetinib, Osimertinib mesylate, Pemetrexed - Non-Small Cell Lung Cancer
Phase 3RecruitingShanghai JMT-Bio Inc.3502025-04-032025-04-08
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Glumetinib Tablets, Osimertinib Mesylate Tablets, Glumetinib Tablets Placebo - Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Phase 2 / Phase 3Not yet recruitingShanghai JMT-Bio Inc.3902025-04-012025-04-03
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
Glumetinib tablets, HB1801 (docetaxel, albumin-bound), Docetaxel - Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
Phase 2Not yet recruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.2562024-07-012024-07-29
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
gumarontinib, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) - Non-small Cell Lung Cancer
Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences912024-06-012024-06-11
Single Dose Glumetinib in Healthy Chinese Male Subjects
Glumetinib - Healthy Volunteers
Phase 1CompletedHaihe Biopharma Co., Ltd.182021-03-022022-08-19
Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
Glumetinib - Negative T790M Mutation and Met Amplification
Phase 1 / Phase 2UnknownHaihe Biopharma Co., Ltd.702019-11-182020-04-08
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Glumetinib - C-Met Exon 14 Mutation
Phase 1 / Phase 2RecruitingHaihe Biopharma Co., Ltd.1832019-07-152022-08-01
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Gumarontinib Tablets - Advanced Solid Tumor
Phase 1CompletedHaihe Biopharma Co., Ltd.1772017-12-162024-11-01
Study to Evaluate the Safety and Anti-tumor Activity of SCC244
Gumarontinib Tablets - Advanced Solid Tumor
Phase 1CompletedHaihe Biopharma Co., Ltd.562017-09-142024-10-09

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Recurrence (2)

Sponsors

Haihe Biopharma Co., Ltd. (5)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2)  ·  Shanghai JMT-Bio Inc. (2)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)

Countries

China (7)  ·  Japan (1)  ·  United States (1)

Top investigators

Dingzhi Huang, Doctor (1)  ·  Fugen Li (1)  ·  James Zhou, MD (1)  ·  Jianying Zhou, Doctor (1)  ·  Jie Wang, PhD (1)  ·  Yilong Wu, M.D. (1)  ·  Yiping Zhang, Doctor (1)  ·  Yongqian Shu, Doctor (1)

Results publications

PMID 39091606, PMID 20610543, PMID 26808342, PMID 30207593, PMID 37096188, PMID 41132955